Intermittent prophylactic antibiotics for bronchiectasis

Area of Science:

• Respiratory Medicine
• Infectious Diseases
• Clinical Pharmacology

Background:

• Bronchiectasis is a chronic airway disorder characterized by permanent dilation, recurrent infections, and inflammation.
• Symptoms like chronic cough and phlegm significantly impact quality of life.
• Prophylactic antibiotics are recommended for frequent exacerbations, but evidence is limited, and antibiotic resistance is a concern.

Purpose of the Study:

• To evaluate the safety and efficacy of intermittent prophylactic antibiotic therapy in adults and children with bronchiectasis.
• To assess the impact on exacerbation frequency and serious adverse events.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) of at least three months' duration.
• Included studies compared intermittent antibiotic regimens (≥14 days on/off) with placebo, usual care, or alternative regimens.
• Primary outcomes were exacerbation frequency and serious adverse events; secondary outcomes included antibiotic resistance and quality of life.

Main Results:

• In adults, 14-day on/off ciprofloxacin regimens slightly reduced exacerbation frequency compared to placebo but significantly increased antibiotic resistance.
• 28-day on/off antibiotic regimens did not reduce overall exacerbation frequency but decreased severe exacerbations; antibiotic resistance risk also increased.
• No significant differences were found in serious adverse events, lung function, or quality of life between antibiotic and placebo groups.

Conclusions:

• Intermittent prophylactic antibiotics in adults with bronchiectasis offer a slight reduction in exacerbations but increase antibiotic resistance.
• The impact of these regimens on children remains unknown due to a lack of studies.
• Further research is required to determine optimal regimens and address safety and efficacy concerns, particularly regarding antibiotic resistance.